Trial Profile
A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Vactosertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 01 Apr 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Jun 2024.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition